RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRX – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.07. RegeneRx Biopharmaceuticals shares last traded at $0.07, with a volume of 230 shares traded.
RegeneRx Biopharmaceuticals Stock Up 5,135.7 %
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue.
Read More
- Five stocks we like better than RegeneRx Biopharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Stock Market Upgrades: What Are They?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
